Description
Pegloxenatide (CAS No. 2420483-82-3) is a glucagon-like peptide-1 receptor (GLP-1 RA) agonist designed for preclinical and laboratory research applications. Pegloxenatide acts by activating GLP-1 receptors, which play a critical role in regulating insulin secretion, glucose homeostasis, and energy metabolism.
This peptide exhibits enhanced stability due to PEGylation, which prolongs its half-life and enables extended receptor activation in laboratory models. By mimicking the action of endogenous GLP-1, Pegloxenatide stimulates insulin secretion in a glucose-dependent manner and modulates glucagon release, providing a valuable tool for metabolic and endocrine research.
Pegloxenatide has been widely used in preclinical research to study type 2 diabetes pathophysiology, insulin sensitivity, and pancreatic beta-cell function. It allows researchers to investigate potential therapeutic mechanisms of GLP-1 receptor agonists, including effects on glucose tolerance, weight management, and metabolic regulation.
Manufactured by a GMP-certified supplier, Pegloxenatide is supplied with a purity of 90%, ensuring reliable and reproducible experimental results. This peptide is provided as a lyophilized powder suitable for in vitro and in vivo laboratory studies. It is available for both wholesale and retail supply.
Laboratory research use only. Not for human or veterinary use.
Product Specifications
| Parameter | Details |
|---|---|
| Product Name | Pegloxenatide |
| Synonyms | PEGylated GLP-1 receptor agonist |
| CAS Number | 2420483-82-3 |
| Purity | 90% |
| Molecular Formula | Proprietary PEGylated peptide structure |
| Appearance | White to off-white lyophilized powder |
| Form | Lyophilized peptide powder |
| Storage | -20°C, protect from light and moisture |
| Applications | Type 2 diabetes research, GLP-1 receptor studies, metabolic regulation |
| Manufacturer | GMP Certified Supplier |
Mechanism of Action & Research Applications
Pegloxenatide functions as a glucagon-like peptide-1 receptor agonist. Upon binding to GLP-1 receptors, it enhances glucose-dependent insulin secretion and suppresses glucagon release, contributing to improved glycemic control in preclinical models. The PEGylation prolongs the peptide’s half-life, enabling sustained receptor activation for experimental studies.
Key research applications include:
Type 2 Diabetes Studies – Evaluating GLP-1 receptor signaling, insulin secretion, and glucose metabolism.
Beta-cell Function Research – Investigating pancreatic islet responses and insulinotropic effects.
Metabolic Regulation Models – Studying effects on weight, appetite, and energy homeostasis.
Preclinical Pharmacology – Assessing long-acting GLP-1 receptor agonist efficacy and pharmacokinetics.
Endocrine Research – Exploring receptor-specific mechanisms in metabolic disease models.
By modulating GLP-1 receptor pathways, Pegloxenatide provides researchers with a reliable tool for understanding metabolic regulation and testing experimental therapeutic strategies in vitro and in vivo.
Development & Research Background
Pegloxenatide was developed as a long-acting, PEGylated GLP-1 receptor agonist to provide extended receptor activation in preclinical models. PEGylation increases stability and decreases enzymatic degradation, making it suitable for laboratory studies that require sustained bioactivity.
Preclinical research with Pegloxenatide has focused on:
Understanding the role of GLP-1 signaling in glucose homeostasis.
Investigating potential therapeutic applications in type 2 diabetes.
Evaluating metabolic, insulinotropic, and glucagon-modulating effects.
Exploring extended-release peptide formulations for research use.
The peptide’s design allows researchers to explore mechanistic insights into GLP-1 receptor activation, beta-cell function, and metabolic disease progression.

Side Effects (For Reference in Research Models Only)
Alterations in glucose metabolism depending on experimental dosage.
Potential modulation of appetite and weight in animal models.
Effects are context-dependent and should be carefully monitored during experimental studies.
Disclaimer
Pegloxenatide is supplied exclusively for laboratory research purposes. It is not intended for human or veterinary use, diagnosis, or therapeutic application.
Keywords
GLP-1 receptor agonist peptide
Pegloxenatide research chemical
GMP Pegloxenatide supplier
Type 2 diabetes research peptide
Pegloxenatide wholesale
PEGylated GLP-1 peptide
Laboratory research peptide
Metabolic regulation research


Reviews
There are no reviews yet.